Queen Margrethe of Denmark, 85, Discharged After Being Hospitalized for a Cold
The 85-year-old former Queen of Denmark has returned to her residence at Fredensborg Palace, according to the Danish Royal House
The Queen's most recent public appearance ahead of the hospitalization was a May 4 peace service at the Church of Our Lady in CopenhagenQueen Margrethe of Denmark was discharged from the hospital on the morning of Saturday, May 10, after being admitted days before as a precaution for a cold.
The Danish Royal House announced the recovery of the former Queen of Denmark, 85, over the weekend.
'Her Majesty is well and is now back in her residence at Fredensborg Palace,' the court said in a statement. She was initially admitted for observation on Thursday, May 8.
The former Queen's hospitalization forced her to cancel a scheduled outing on May 8, a visit to the Sankt Lukas Foundation's 125th anniversary celebration. Queen Margrethe's latest public appearance ahead of the hospitalization was at a May 4 peace service at the Church of Our Lady in Copenhagen to mark the 80th anniversary of Denmark's liberation.
The Queen abdicated her position in January 2024 on the 52nd anniversary of her rise to the throne, becoming the first Danish royal to voluntarily do so in almost 900 years.
Her eldest son, now known as King Frederik, acceded to the throne later that month, and his Australian-born wife became Queen Mary.
Can't get enough of PEOPLE's Royals coverage? to get the latest updates on Kate Middleton, Meghan Markle and more!
The Queen cited her health during a New Year's Eve 2023 speech announcing her abdication.
"In February this year, I underwent extensive back surgery. Everything went well, thanks to the competent health personnel, who took care of me," she said in part then. "Inevitably, the operation gave cause to thoughts about the future – whether now would be an appropriate time to pass on the responsibility to the next generation. I have decided that now is the right time."
In 2023, the Queen made history as Denmark's longest-reigning monarch after decades of service.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics
CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging System The VxWave Ultrasound Imaging System potentially provides important insights into vascular access, to possibly enable earlier creation and use of AV fistula Results to be presented at American Society of Nephrology (ASN) Annual Meeting in November SYDNEY and SAN ANTONIO, July 30, 2025 /PRNewswire/ -- Vexev, an Australian-based medical device company advancing next-generation vascular imaging, and U.S. Renal Care, a leading provider of in-center and home dialysis in the United States, today announced the successful completion of enrollment in the CANSCAN clinical trial (NCT06691672). The first-of-its-kind, multi-center feasibility study enrolled 120 patients with chronic kidney disease to evaluate the use of semi-autonomous ultrasound scanning utilizing the VxWave Ultrasound Imaging System for arteriovenous (AV) fistula mapping in dialysis clinics. "The VxWave ultrasound system may remove one of the biggest hurdles in the creation of vascular access. Patients could have vascular mapping conducted in their dialysis facility, enabling a more efficient way to obtain a permanent vascular access point," commented Varshi Broumand, MD, MHA, FACP, FASN, Interventional Nephrologist at South Texas Renal Care Group and CANSCAN Study Principal Investigator. "Performing the ultrasound scans during the clinic visit would make AV fistula mapping more convenient and timely and potentially avoid sending patients to additional imaging appointments." An AV fistula is a connection made between an artery and a vein, typically in the arm, to create an access point for patients requiring dialysis. This allows blood to flow quickly and easily during treatment, which helps the body remove toxins more effectively. The VxWave Ultrasound Imaging System is a robotic tomographic ultrasound system specifically designed for upper limb vascular imaging - integrating advanced robotics, machine learning and ultrasound signal processing to create a 3D vascular model and detailed report that potentially provides insights into vascular access points - all at the point of care. "Validating this concept is the first step toward a future where intelligent machines can perform high-precision medical imaging without a human hand on the probe. The potential for a robotic system guided by AI, delivering real clinical value - it's not science fiction anymore," said Shannon Thomas, MD, Chief Medical Officer, Vexev. "The real excitement begins when this can change lives, not just lab results. This is a huge step forward in our mission to improve the lives of millions of people worldwide living with end-stage kidney disease." "U.S. Renal Care is committed to delivering innovative treatments that address the most critical needs for people living with kidney disease," said Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs, U.S. Renal Care. "The CANSCAN trial of the VxWave Ultrasound Imaging System opens the possibility of integrating semi-autonomous ultrasound imaging into our workflow and improving patient outcomes, by allowing patients to receive life-saving permanent vascular access placed in the optimal location, as quickly as possible." About VexevVexev is an Australian med‑tech startup founded in 2018 by Drs. John Carroll and Eamonn Colley - University of New South Wales (UNSW) PhD graduates in vascular fluid dynamics and computational imaging. Vexev is on a mission to improve lives by developing the next generation of vascular imaging solutions. Visit to learn more. About U.S. Renal CareU.S. Renal Care, the fastest-growing dialysis provider in the nation, partners with nephrologists across 32 states in the U.S. to care for more than 36,000 people living with kidney disease. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence - delivering the best experience and outcomes for our patients. Visit to learn more. Photo - - View original content: SOURCE Vexev Sign in to access your portfolio
New York Post
12 hours ago
- New York Post
Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year. 4 Wegovy maker Novo Nordisk is battling rising competition in the obesity drug market. Patrick Bay Damsted – 'The magnitude of the guidance cut is a shocker,' Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than 'compounded' copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. US law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the US, both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. 4 Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. REUTERS At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the US market. 'The stock has gone from being a market darling to one of its biggest letdowns,' said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. 'The biggest concern is the illegal channel siphoning away market share – something that's hard to quantify. Rebuilding trust will take time.' New CEO an insider Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. 4 Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. Tobias Arhelger – 'We need to increase the sense of urgency and execute differently,' Doustdar told investors and analysts on a call. 'The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear.' Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. 4 Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. REUTERS In May, Novo said it expected many of the roughly one million US patients using compounded GLP-1 drugs to switch to branded treatments after a Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. 'Unfortunately, our latest market research indicates that has not happened,' Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more US patients are still using compounded GLP-1s, he said. Novo has stepped up its dialog with the US FDA to limit unlawful compounding of its drugs, the head of US operations David Moore added on the call. 'Compounding continues to be an issue that we have to address,' Moore said.
Business of Fashion
13 hours ago
- Business of Fashion
Ozempic Maker Novo Nordisk's Market Value Drops $93 Billion
Novo Nordisk named its head of international operations as chief executive officer after slumping weight-loss drug sales led to a profit warning that wiped $93 billion off its market value. The Danish drugmaker promoted Maziar Mike Doustdar, who has spent more than three decades with the company, to the top spot. The surprise choice disappointed investors who were hoping for a high-profile outsider to lead a fresh challenge to Eli Lilly & Co., which has been pulling ahead of Novo in the obesity market. The appointment came shortly after Novo slashed its financial forecast, predicting this year's sales will grow 8 to 14 percent, while operating profit expands 10 to 16 percent, based on constant exchange rates. That compares with its previous growth forecasts of as much as 21 and 24 percent, respectively. Shares of Novo plunged as much as 30 percent in Copenhagen, the biggest intraday drop on record. ADVERTISEMENT Doustdar said he plans to 'increase the sense of urgency and execute differently,' and his top priorities will be advancing Novo's drug pipeline, innovation and investing to deliver growth. The new CEO, who takes over on Aug. 7, also said on a call with journalists that he's planning to review the company's cost base, without citing specific targets for cuts. That indicates Novo is preparing for a period of slower growth after the initial surge of demand for its blockbuster obesity drug, Wegovy, that briefly made the company Europe's biggest by market value. 'Analysts will start to question both near-term and longer-term obesity expectations that have ballooned out of control,' said Jared Holz, a health-care strategist at Mizuho Securities USA LLC. Holz and other analysts questioned whether an insider will be able to restore investor confidence. Given the company's recent struggles, 'we are surprised by the choice of an internal candidate,' said Benjamin Jackson, an analyst at Jefferies LLC. Novo announced the ouster of former CEO Lars Fruergaard Jorgensen in May, seeking a reset following a string of setbacks. Though Doustdar, 54, is an insider at Novo, he brings a more international background than some of the company's previous leaders. He's Iranian-born, with Austrian citizenship. Novo's past CEOs have all been Danish and were intertwined with the company prior to taking over. Two were sons-in-law of previous company leaders. After enjoying an early advantage as a first mover in the obesity drug market, Novo is struggling with competition as Lilly's Zepbound wins market share over Wegovy. Lilly also appears better positioned to dominate for years to come. It has an easy-to-take weight-loss pill that will come to market as soon as early 2026 and it's studying a shot that's shown signs of being as effective as bariatric weight-loss surgery. Novo's own next-generation candidate, CagriSema, has fallen short of both the company's and analysts' hopes in clinical trials. ADVERTISEMENT The company is also facing competition from compounding pharmacies that are allowed to make copies of drugs when they are in short supply. Novo estimates about 1 million patients in the US are using compounders in the US market, Chief Financial Officer Karsten Munk Knudsen said on a call. Novo said it will fight compounding in the courts and invest in its own direct-to-patient marketing efforts. Novo has said a new contract with CVS Health Corp. for Wegovy would drive volume from July 1. The slashed forecast reflects competition for both Wegovy and its sister drug Ozempic for diabetes, the company said. The drugmaker also cited slower than expected market growth for weight-loss drugs. Novo's sales climbed 18 percent in constant currencies in the second quarter, the company said, with operating profit rising 40 percent. The company will publish complete second-quarter results on Aug. 6. The foundation that controls the company pushed for Jorgensen to go and instated his predecessor, Lars Rebien Sorensen, as an observer on Novo's supervisory board. Sorensen is set to return as a full board member next year. By Naomi Kresge, with assistance from Christian Wienberg, Lisa Pham, Thomas Hall and Marthe Fourcade Learn more: Zepbound Beats Wegovy in First Head-to-Head Trial Eli Lilly's GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk's Wegovy, according to the trial results.
